Threshold’s Glufosfamide Misses Endpoint In Phase III For Refractory Pancreatic Cancer

Final results from separate Phase II first-line pancreatic cancer trial with Lilly’s Gemzar due in third quarter; company had reported “encouraging” top-line data in December.